MetaphysicalCells

MetaphysicalCells

Share this post

MetaphysicalCells
MetaphysicalCells
Weekly TechBio News (I)

Weekly TechBio News (I)

Latest News: Lantern Pharma, Insilico Medicine, Manas AI, LinkGevity, Certara, Tevogen Bio, Retro Biosciences, Model Medicine and Isomorphic Labs

Marina T Alamanou's avatar
Marina T Alamanou
Feb 06, 2025
∙ Paid
2

Share this post

MetaphysicalCells
MetaphysicalCells
Weekly TechBio News (I)
1
Share
Weekly TechBio News

For today’s latest TechBio news:

  • 🛵 Weekly TechBio News (I)

    Latest News: Lantern Pharma, Insilico Medicine, Manas AI, LinkGevity, Certara, Tevogen Bio, Retro Biosciences, Model Medicine and Isomorphic Labs

  • 🛵 Weekly TechBio News (II)

    Latest News: Phenaros Pharmaceuticals, Acellera Therapeutics, Artificial Inc, Owkin, Innophore, Algorae Pharmaceuticals, Okomera, Ultima Genomics, Araceli Bioscience and many more

“Without deviation from the norm, progress is not possible.”


Frank Zappa

Weekly TechBio News (I)

🪐 Lantern Pharma Inc

Lantern Pharma (NASDAQ: LTRN) announced on January 27, 2025 advancements in the application of its RADR AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs) (Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer) and is actively advancing multiple ADC candidates through preclinical development, including a promising collaboration with the prestigious MAGICBULLET::Reloaded Initiative at the University of Bielefeld in Germany.

More specifically, in a study published in PLOS ONE (Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis), Lantern Pharma demonstrated how their AI-driven approach successfully identified 82 promising ADC targets and 290 target-indication combinations, while also validating 729 potential payload molecules from a screening of over 50,000 compounds. The key highlights of the AI-powered ADC module include:

  • Successful identification of 22 clinically proven targets with established therapeutic potential.

  • Discovery of 60 novel targets that present significant opportunities.

  • Development of proprietary mutation-specific targeting capabilities that enable improved clinical trial design, enhanced precision in indication selection and more accurate patient response predictions.

  • Establishment of a framework that could reduce ADC development costs by up to 60% and accelerate development timelines by 30-50%.

  • Creation of a highly scalable, ML ready approach that leverages the RADR™ AI platform to systematically evaluate thousands of potential tumor sub-types and indications.

Furthermore, the highlights of Lantern’s AI-Powered Pipeline are:

  • LP-184 continues to advance through its Phase 1a first-in-human trial (NCT05933265) across multiple solid tumor indications.

  • Patients with recurrent glioblastoma (GBM) have been enrolled in the LP-184 Phase 1a trial at 2 academic centers, including Johns Hopkins and 1 community site. The data will help guide later stage clinical development planned to be sponsored by Starlight Therapeutics (Lantern’s subsidiary) during early 2025.

  • LP-184, which will be developed as STAR-001 for CNS and other neuro-oncology indications, received Fast Track Designation in GBM from the FDA.

  • Three U.S. FDA Rare Pediatric Disease Designations were granted to LP-184 in three ultra rare children’s cancers.

  • LP-284 Phase 1a clinical trial: They are in the process of opening additional hematology-focused sites later this year, with the potential to advance to Phase 1b or 2 by early to mid 2025.

  • LP-300 in the Harmonic™ Phase 2 Clinical Trial for never-smoker patients with non-small cell lung cancer (NSCLC) demonstrated encouraging preliminary results when combined with standard-of-care chemotherapy (pemetrexed and carboplatin), achieving an 86% clinical benefit rate and a 43% objective response rate.

  • The Harmonic™ Trial has been expanded to both Japan and Taiwan with an expected 10 sites in East Asia; 5 in each country where the population of never-smokers is 33 to 35 percent of new cases in NSCLC.

  • For more details:

    I: TechBio Latest News & Updates

    I: TechBio Latest News & Updates

    Marina T Alamanou
    ·
    October 24, 2024
    Read full story

MetaphysicalCells is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Marina T Alamanou
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share